Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Front Med. 2022 Oct;16(5):714-722. doi: 10.1007/s11684-021-0888-8. Epub 2022 May 4.
A new definition of metabolic dysfunction-associated fatty liver disease (MAFLD) has recently been proposed. We aim to examine the associations of MAFLD, particularly its discordance from non-alcoholic fatty liver disease (NAFLD), with the progression of elevated brachial-ankle pulse wave velocity (baPWV) and albuminuria in a community-based study sample in Shanghai, China. After 4.3 years of follow-up, 778 participants developed elevated baPWV and 499 developed albuminuria. In comparison with the non-MAFLD group, the multivariable adjusted odds ratio (OR) of MAFLD group for new-onset elevated baPWV was 1.25 (95% confidence interval (CI) 1.01-1.55) and 1.35 (95% CI 1.07-1.70) for albuminuria. Participants without NAFLD but diagnosed according to MAFLD definition were associated with higher risk of incident albuminuria (OR 1.77; 95% CI 1.07-2.94). Patients with MAFLD with high value of hepamet fibrosis score or poor-controlled diabetes had higher risk of elevated baPWV or albuminuria. In conclusion, MAFLD was associated with new-onset elevated baPWV and albuminuria independently of body mass index, waist circumference, and hip circumference. Individuals without NAFLD but diagnosed as MAFLD had high risk of albuminuria, supporting that MAFLD criteria would be practical for the evaluation of long-term risk of subclinical atherosclerosis among fatty liver patients.
最近提出了代谢功能障碍相关脂肪性肝病（MAFLD）的新定义。我们旨在研究 MAFLD，尤其是其与非酒精性脂肪性肝病（NAFLD）的不一致性，与中国上海社区研究样本中升高的肱踝脉搏波速度（baPWV）和白蛋白尿进展的关系。经过 4.3 年的随访，778 名参与者出现了升高的 baPWV，499 名参与者出现了白蛋白尿。与非 MAFLD 组相比，MAFLD 组新发升高的 baPWV 的多变量调整比值比（OR）为 1.25（95%置信区间（CI）1.01-1.55）和 1.35（95%CI 1.07-1.70）用于白蛋白尿。根据 MAFLD 定义诊断但无 NAFLD 的参与者发生白蛋白尿的风险较高（OR 1.77；95%CI 1.07-2.94）。MAFLD 患者伴有高肝纤维化评分或糖尿病控制不佳，其发生升高的 baPWV 或白蛋白尿的风险更高。总之，MAFLD 与新发生的升高的 baPWV 和白蛋白尿独立于体重指数、腰围和臀围相关。无 NAFLD 但诊断为 MAFLD 的个体发生白蛋白尿的风险较高，支持 MAFLD 标准可用于评估脂肪肝患者亚临床动脉粥样硬化的长期风险。
World J Gastroenterol. 2015-9-21
Nutr Metab Cardiovasc Dis. 2024-7
Nutr Metab Cardiovasc Dis. 2024-8
Liver Int. 2021-2
Lancet Gastroenterol Hepatol. 2021-1
Lancet Gastroenterol Hepatol. 2021-1
Lancet Diabetes Endocrinol. 2020-7
Liver Int. 2020-9
Gastroenterology. 2020-5
Zotero 插件